Physician profile
Norman S Abbott
NPI 1679582142
$8,955.51
in general payments reported to CMS, 2019-2025
43 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $944 · 2020: $797 · 2021: $1,375 · 2022: $1,353 · 2023: $1,363 · 2024: $1,370 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,297 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,296.61 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,022.78 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.66 | 2019-2025 | Jardiance |
| Abbott Laboratories | $593.99 | 2019-2023 | Cardiomems |
| Actelion Pharmaceuticals US, INC. | $593.60 | 2019-2025 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $591.86 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $579.96 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $535.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $529.58 | 2019-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $432.82 | 2019-2024 | Farxiga |
| Pfizer INC. | $387.53 | 2019-2025 | |
| Scpharmaceuticals INC. | $378.20 | 2024-2025 | |
| Novo Nordisk INC | $357.59 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $355.78 | 2019-2025 | |
| Philips North America LLC | $190.69 | 2022-2025 | Mcot, (Ck4) Mcot, Extended Holter |
| Boston Scientific Corporation | $182.99 | 2020-2025 | Watchman Flx, Cds - Mct/Cem Monitoring, Watchman Access System |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.